Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D6OO
|
|||
| Former ID |
DNCL002901
|
|||
| Drug Name |
NP-500
|
|||
| Indication | Metabolic syndrome x [ICD-11: 5C50-5D2Z] | Phase 1 | [1] | |
| Type-2 diabetes [ICD-11: 5A11] | Phase 1 | [1] | ||
| Company |
Napo Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024901) | |||
| REF 2 | Napo Receives Commitments for a Private Placement of Common Shares and Enters into Binding Letter of Intent for Intellectual Property License. Napo. JANUARY 08, 2007 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.